Venkateswaran, R (2012) Supplementation of Aripiprazole In Risperidone induced Hyperprolactinemia a Double Bling Randomized Placebo Controlled Trial. Masters thesis, PSG Institute of Medical Sciences & Research, Coimbatore.
|
Text
201801212venkateswaran.pdf Download (1MB) | Preview |
Abstract
INTRODUCTION : This scale is designed to assess positive symptoms, principally those that occur in schizophrenia. It is intended to serve as a complementary instrument to the Scale for the Assessment of Negative Symptoms (SANS). These positive symptoms include hallucinations, delusions, bizarre behavior, and positive formal thought disorder. As in the case of the SANS, the investigator using this instrument will need to decide on an appropriate "time set". The instrument was developed with the exception that, in general, the time set will cover the past month as in the case of SANS. This scale can also be used in psychopharmacologic research in order to make weekly ratings and chart the subject's response to treatment. Investigators using this instrument, particularly in combination with the SANS, will need to use a standard clinical interview in order to evaluate the subject's symptoms. Since positive formal thought disorder is an important positive symptom, it is recommended that, in doing this interview, the investigator begin talking with the subject on a relatively neutral topic for five to ten minutes in order to observe the subject's manner of speaking and responding. Thereafter, he can begin to ask specific questions about the various positive symptoms. Suggested probes are provided in the interview guide. OBJECTIVE: Hyperprolactinemia and related adverse effects often occur with antipsychotics, especially Risperidone. We investigated the effect of adjunctive treatment with Aripiprazole on hyperprolactinemia in patients with schizophrenia maintained on Risperidone. METHOD: Thirty patients who were on stable doses of Risperidone were randomized either to get 10 mg of Aripiprazole or placebo in a double bind fashion. Serum prolactin levels were measured at the baseline and at the end of 8 weeks. Symptoms and side effects were assessed with the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment for positive symptoms, Scale for Assessment of Negative symptoms, Simpson- Angus Rating scale, Barnes Akathisia Rating Scale, Arizona Sexual Experience Scale and Prolactin Related Adverse Event Questionnaire at baseline, weeks 2, 4, 6 and 8. RESULTS: Prolactin levels of patients receiving Aripiprazole significantly decreased compared to the placebo group, at the end of 8 weeks. In the Aripiprazole group, patients had 60.64% reduction in prolactin level at week 8 whereas no reduction was observed in placebo. Statistically significant reduction in scores of Arizona Sexual Experience Scale and Prolactin Related Adverse Event Questionnaire were noted in Aripiprazole group which denote improvement in sexual side effects. No differences were observed on BPRS, Scale for the Assessment of Positive symptoms, Scale for Assessment of Negative Symptoms, Simpson-Angus Rating Scale, and Barnes Akathisia Rating scale scores were noted. CONCLUSION: Adjunctive Aripiprazole treatment improved hyperprolactinemia in both gender, resulting in clinical improvement, with no significant effects on psychopathology and extra pyramidal symptoms. Partial agonistic property of Aripiprazole could be the cause of this observation.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | 20096551 |
| Uncontrolled Keywords: | Aripiprazole, Risperidone, Hyperprolactinemia, Double Bling Randomized, Placebo Controlled Trial. |
| Subjects: | MEDICAL > Psychiatry |
| Depositing User: | Subramani R |
| Date Deposited: | 16 Aug 2017 00:52 |
| Last Modified: | 12 Sep 2020 04:23 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/1871 |
Actions (login required)
 |
View Item |
